| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.079 | 0.01 |
| mRNA | XMD13-2 | GDSC1000 | pan-cancer | AAC | 0.088 | 0.01 |
| mRNA | BRD-K34222889 | CTRPv2 | pan-cancer | AAC | 0.087 | 0.01 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | 0.091 | 0.01 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.096 | 0.01 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.01 |
| mRNA | PD-0332991 | GDSC1000 | pan-cancer | AAC | -0.097 | 0.01 |
| mRNA | phloretin | CTRPv2 | pan-cancer | AAC | 0.093 | 0.01 |
| mRNA | GW843682X | CTRPv2 | pan-cancer | AAC | 0.093 | 0.01 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | 0.084 | 0.01 |